Archive for the ‘Lyme’ Category

Lyme Disease Coinfections & the Brain

http://

Feb 26, 2026
Clinical Strategies for Neuropsychiatric and Neurological Recovery
Join Dr. Aylin Ozdemir for an expert-led exploration of the neurological and neuropsychiatric complexities of Lyme disease and associated co-infections, based on a recently published peer-reviewed research paper (June 2025).
This webinar examines why Lyme disease is frequently misdiagnosed in patients presenting with cognitive, behavioural, and neurological symptoms, and how expanded diagnostic approaches can reveal underlying immune dysregulation and neuroinflammation when standard testing falls short.
Drawing from real-world clinical cases, viewers will learn about integrative therapeutic approaches to support neurological and neuropsychiatric recovery. We’ll explore practical strategies to better recognise, treat, and support recovery in complex neuro-Lyme presentations:
Why Lyme disease often presents as psychiatric or neurological illness The limitations of standard testing How expanded diagnostics improve detection Clinical insight: Real-world case examples Recognising complex neuropsychiatric presentations Integrative therapeutic approaches: Antimicrobial strategies Immune modulation Neuroprotective and mitochondrial support Long-term maintenance protocols to help reduce relapse Dr. Kunal Garg provides a brief overview of the application of CARE Guidelines, highlighting the importance of rigorous case documentation and high-quality publishing in advancing evidence-informed Lyme disease care.
For more:

Bartonella and Borrelia-Related Disease Presenting as a Neurological Condition Revealing the Need for Better Diagnostics

https://www.mdpi.com/2076-2607/12/1/209

Bartonella and Borrelia-Related Disease Presenting as a Neurological Condition Revealing the Need for Better Diagnostics

by Marna E. Ericson1, B. Robert Mozayeni1, Laurie Radovsky2 and Lynne T. Bemis3,*
1T Lab Inc., Gaithersburg, MD 20878, USA
2Laurie Radovsky, M.D. LLC., St. Paul, MN 55102, USA
3Department of Biomedical Sciences, Medical School Duluth Campus, University of Minnesota, Duluth, MN 55812, USA
*Author to whom correspondence should be addressed.
Microorganisms 2024, 12(1), 209; https://doi.org/10.3390/microorganisms12010209
Submission received: 21 December 2023 / Revised: 16 January 2024 / Accepted: 18 January 2024 / Published: 19 January 2024
(This article belongs to the Special Issue Bartonella and Bartonellosis: New Advances and Further Challenges)

Abstract

The diagnostic tests available to identify vector-borne pathogens have major limitations. Clinicians must consider an assortment of often diverse symptoms to decide what pathogen or pathogens to suspect and test for. Even then, there are limitations to the currently available indirect detection methods, such as serology, or direct detection methods such as molecular tests with or without culture enrichment. Bartonella spp., which are considered stealth pathogens, are particularly difficult to detect and diagnose. We present a case report of a patient who experienced a spider bite followed by myalgia, lymphadenopathy, and trouble sleeping. She did not test positive for Bartonella spp. through clinically available testing. Her symptoms progressed and she was told she needed a double hip replacement. Prior to the surgery, her blood was submitted for novel molecular testing, where Bartonella spp. was confirmed, and a spirochete was also detected. Additional testing using novel methods over a period of five years found Bartonella henselae and Borrelia burgdorferi in her blood.
This patient’s case is an example of why new diagnostic methods for vector-borne pathogens are urgently needed and why new knowledge of the variable manifestations of Bartonellosis need to be provided to the medical community to inform and heighten their index of suspicion.
_____________
**Comment**
You will recognize Marna Ericson’s name as her son had a severe bartonella infection.  She managed to take advanced imaging techniques on samples and found Bartonella alive and well in tissues surrounding where a PIC line had been removed.  She has teamed up with other researchers investigating Bartonella.  We can be extremely thankful for their work.
For more:

The Great Alzheimer’s Scam & the Proven Cures They’ve Buried For Billions

https://www.midwesterndoctor.com/p/the-great-alzheimers-scam-and-the

The Great Alzheimer’s Scam and The Proven Cures They’ve Buried for Billions

Decades of neglect in understanding the actual causes of dementia have transformed it into one of the most costly diseases in existence.

• Alzheimer’s disease is commonly thought to result from abnormal plaque buildup in the brain that gradually destroys brain tissue. As a result, almost all Alzheimer’s research has been directed toward eliminating amyloid, even after the basis for much of this work was shown to stem from fraudulent research.

•As such, despite decades of research and billions of dollars spent, this model has completely failed to produce useful results. The costly “groundbreaking” Alzheimer’s drugs only slightly slow dementia progression—at the expense of causing brain bleeding and swelling in over a quarter of those treated.

•In contrast, numerous affordable treatments have been developed for Alzheimer’s disease that target the root causes of the disorder, producing significant benefits at a fraction of the cost and without any toxicity.

•One neurologist, for example, proposed that amyloid serves a protective function in the brain and treats Alzheimer’s by identifying the underlying process causing dementia (which can often be diagnosed through symptoms). Remarkably, despite the method being proven in clinical research, awareness of it or the fact there are completely different types of “Alzheimer’s disease” which require different treatments remains almost nonexistent.

•Likewise, a strong case can be made that impaired cerebral circulation, along with impaired venous and lymphatic drainage, plays a pivotal role in Alzheimer’s disease.

•This article will review the common causes of cognitive impairment and dementia (e.g., cells becoming trapped in a shocked state where they no longer function) along with the forgotten treatments for neurodegenerative disorders—some of which, like DMSO, have extensive evidence supporting their use.

Dr. Dale Bredesen detailed in The End of Alzheimer’s, a few pivotal conclusions:

  • Amyloid protein is a protective mechanism the brain uses to protect itself from other stressors that endanger brain tissue.
  • Rather than there being one type of Alzheimer’s, there are actually three with different symptoms, and it is essential to recognize which type someone has before initiating treatment.
    • Type 1: Inflammatory – often metabolic or infectious
      • Type 1.5 Glycotoxic (hybrid of types 1&2) insulin resistance and chronically elevated blood sugar
    • Type 2: Atrophic – deficiences in nutrients, hormones, and other factors
    • Type 3: Toxic – exposure to mold, chronic infections such as Lyme disease, Herpesvirus, cytomegalovirus, fungal infections, etc. heavy metals, and household chemicals
    • Type 4: Vascular – hypertension, atherosclerosis, or anything causing chronic restriction of cerebral blood flow
    • Type 5: Traumatic – brain injury
  • The brain is designed to be able to adapt to the needs of life, so it is always creating or pruning neural connections and brain cells. Alzheimer’s, in turn, results from the loss of signals that sustain brain cells, and the dismantling of neural connections outweighing the formation of new ones, gradually compounding over the decades.

As such, his formula was fairly straightforward: identify the type of Alzheimer’s someone has, eliminate its causes, and gradually wait for the physiological momentum to shift from neurodegeneration to neurodevelopment.  (See link for article)

____________

**Comment**

Many anecdotal reports of using DMSO successfully for dementia are given in the article.

For more:

 

 

Valneva’s Strategic Bet: Lyme Vaccine Holds Their Key to the Future (But Not Yours)

https://www.ad-hoc-news.de/boerse/news/ueberblick/valneva-s-strategic-bet-lyme-disease-vaccine-holds-key-to-future/68636490

Valneva’s Strategic Bet: Lyme Disease Vaccine Holds Key to Future

05.03.2026 | boerse-global.de

Valneva’s future hinges on its Lyme disease vaccine candidate, with final Phase 3 data expected in H1 2026. The stock has surged on anticipation, while its Chikungunya vaccine faces U.S. delays.

Valneva's Strategic Bet: Lyme Disease Vaccine Holds Key to Future - Foto: über boerse-global.de
Valneva’s Strategic Bet: Lyme Disease Vaccine Holds Key to Future – Foto: über boerse-global.de

At the TD Cowen Health Care Conference in Boston this week, executives from the French biotech firm Valneva outlined their strategic roadmap to institutional investors. The presentation by CEO Thomas Lingelbach and CFO Peter Buhler placed overwhelming emphasis on a single, pivotal asset: its candidate for a Lyme disease vaccine. The company’s future trajectory appears heavily dependent on this program, with final Phase 3 data anticipated in the first half of 2026.

A High-Stakes Clinical Catalyst

Valneva is advancing the pivotal Phase 3 trial for what could become the world’s only Lyme disease vaccine in late-stage development, in collaboration with pharmaceutical giant Pfizer. The U.S. Food and Drug Administration (FDA) has already granted the project Fast Track designation. Should the upcoming topline results confirm both efficacy and safety, Pfizer intends to submit applications for regulatory approval to the FDA and the European Medicines Agency (EMA) before the end of 2026.

This binary event is reflected in the equity’s performance. Valneva shares currently trade at €4.73, having nearly doubled in value over the past twelve months. This valuation incorporates significant market expectations for a positive trial outcome. Investor anxiety ahead of the data release is further evidenced by the stock’s substantial volatility, which stands above 53% on a 30-day basis. (See link for article)

_____________

**Comment**

Despite experts and advocates shouting at the top of their lungs that Valneva’s VLA15 Lyme vaccine is based on similar OspA-based tech as LYMErix which is responsible for 1000+ adverse reactions and ongoing severe complications, the FDA predictably gave it fast-track designation.  This should not surprise anyone.  The FDA could give two hoots about whether or not a ‘vaccine’ is truly ‘safe and effective.’

Just look at the clot shot for affirmation of this simple fact.  It has caused more adverse reactions and death than ANY other vaccine in the history of VAERS yet it’s still on the market amidst cries to pull it off the market, and despite being absolutely worthless with negative efficacy the more shots you get.

Declassified Docs Link Bioweapon Program to Lyme Disease

http://

Radioactive Ticks

Dr. Robert Malone

March 5, 2026

Important point: Malone states that the Lone Star Tick has spread due to purposely deployed radio active ticks in Virginia by our government.  (It ain’t climate change!  Please hear me)

https://www.malone.news/p/declassified-documents-link-us-bioweapons

Declassified Documents Link U.S. Bioweapons Program to Lyme Disease Outbreak

Exclusive: Military released 282,800 radioactive ticks, suppressed co-infection research for 40 years

An extensive investigation based on declassified government documents and previously suppressed scientific research has uncovered compelling evidence that U.S. biological weapons programs contributed to the emergence of Lyme disease, which now affects hundreds of thousands of Americans annually.

The investigation reveals a pattern of concealment spanning six decades, including the systematic suppression of critical medical research and the release of nearly 300,000 radioactive ticks across Virginia to study how the disease-carrying insects would spread.

CIA Deployed Infected Ticks Against Cuba

Declassified documents and testimony from a CIA operative describe the 1962 deployment of infected ticks against Cuban sugarcane workers as part of Operation Mongoose, the Kennedy administration’s effort to destabilize Fidel Castro’s regime.

The operative, now in his seventies, told researchers that the “strangest thing he ever did was drop infected ticks on Cuban sugarcane workers” using C-123 transport aircraft flying nighttime missions “almost skimming the surface of the Caribbean to avoid Cuban radar.”

After returning from Cuba, the operative’s four-month-old son developed life-threatening fever requiring emergency surgery. His CIA commander advised him to “burn all the clothes you took to Cuba. Burn everything,” indicating contamination concerns.

The deployment was canceled when “Cuba’s shifting winds made accurate payload delivery difficult,” according to the operative’s account.

Massive Domestic Tick Experiments

Between 1966 and 1969, the U.S. military released 282,800 lone star ticks made radioactive with Carbon-14 across Virginia sites along bird migration routes. The radioactive marking allowed researchers to track the ticks’ spread using Geiger counters over several years.

Before these experiments, lone star ticks were not found above the Mason-Dixon Line. Within years of the Virginia releases, they had established populations on Long Island for the first time. Two tick experts consulted about these releases said they “were aghast” and “you’d never be able to do that now.”

The Swiss Agent Cover-Up

In 2014, researchers discovered extensive unpublished materials in the garage of deceased scientist Willy Burgdorfer, who identified the bacterium that causes Lyme disease. The materials revealed that Burgdorfer had found a second pathogen called “Swiss Agent” in Lyme patient blood samples from Connecticut and Long Island in the late 1970s.

Blood from Lyme patients showed “very strong reactions” to Swiss Agent testing, but this finding was completely omitted from Burgdorfer’s landmark 1982 study that identified the Lyme disease bacterium. The suppression of this research for over 40 years may have contributed to treatment failures in chronic Lyme patients.

Dr. Jorge Benach and Dr. Allen Steere, co-authors of the 1982 study, now acknowledge that Swiss Agent research “should be done” because “public health concerns warrant a closer look.”

Project 112: The Hidden Bioweapons Expansion

Defense Secretary Robert McNamara authorized Project 112 in 1962, creating what researchers describe as a bioweapons program “almost as large and secretive as the Manhattan Project.” The program involved 134 scheduled tests from 1962-1974 with production facilities capable of breeding 100 million infected mosquitoes monthly and 50 million fleas weekly.

The program’s existence was “categorically denied by the military” until 2000, when a CBS News investigation forced acknowledgment. Documents show the program involved “every branch of the U.S. armed services and intelligence agencies” with testing sites spanning multiple countries.

Operation Big Itch in 1954 successfully deployed 670,000 fleas from cluster bombs, proving arthropods could survive aerial deployment and “soon attached themselves to hosts.” The test validated bioweapons capable of covering “a battalion-sized target area and disrupt operations for up to one day.”

The Plum Island Connection

Plum Island Animal Disease Center sits just 13 miles from Lyme, Connecticut, where the disease was first identified. From 1952-1969, the facility was managed by the Army Chemical Corps for biological warfare research before transfer to the Department of Agriculture.

The facility “frequently conducted its experiments out of doors” with acknowledged containment failures where “test animals mingled with wild deer, test birds with wild birds.” Richard Endris maintained “over 200,000 soft and hard ticks of varying species in tick nurseries on Plum Island, personally collected from locations as far away as Cameroon, Africa.”

Wildlife regularly moved between Plum Island and the mainland. “Deer from Lyme regularly swam to Plum Island, and local birds flew there to feed on insects,” creating direct pathways for laboratory pathogens to reach wild populations.

Disease Emergence Timeline

The Long Island Sound region experienced an unprecedented outbreak of tick-borne diseases beginning in 1968:

  • 1968: First Eastern U.S. human babesiosis cases appear on Nantucket
  • 1968: Rocky Mountain spotted fever appears in Cape Cod region
  • 1970: Hundreds of Rocky Mountain spotted fever cases documented on Long Island
  • 1972: First 51 documented Lyme arthritis cases in Old Lyme, Connecticut

“By the 1990s, the eastern end of Long Island had by far the greatest concentration of Lyme disease,” according to one analysis. “If you drew a circle around the area of the world heavily impacted by Lyme disease, the center of that circle was Plum Island.”

Burgdorfer’s Cryptic Admissions

Willy Burgdorfer, who discovered the Lyme disease bacterium in 1982, spent most of his career developing tick-borne biological weapons before transitioning to civilian research. In 2013 video testimony, he confirmed participation in bioweapons research and “insinuated there had been an accidental release of some sort.”

After cameras stopped rolling, “Willy told us with a smile, ‘I didn’t tell you everything.’ But try as we might, we couldn’t get him to say more.” Before his death in 2014, he left a note stating “I wondered why somebody didn’t do something.”

In 2007, when documentary filmmakers attempted to interview Burgdorfer, a government scientist “pounded on the door” demanding to “sit in on this interview,” indicating ongoing official concern about his potential disclosures.

Pattern of Institutional Concealment

The investigation identified systematic concealment behaviors spanning multiple decades:

  • Project 112 denied for 50 years despite extensive documentation
  • Swiss Agent research suppressed despite public health relevance
  • Relevant documents kept classified long after security justifications expired
  • Congressional investigation requirements resisted
  • Laboratory origin questions characterized as “conspiracy theories”

(See link for article & comprehensive integrated multi-layered analysis of the issue)

_____________

**Comment**

An AI-enhanced retrospective analysis found:

  • phylogenetic gaps between ancient strains and the strains that emerged in the 60’s & 70’s (in other words, what we are infected with isn’t found in nature – it’s been tweaked in a lab)
  • co-infection clustering of three distinct diseases in the same geographical area and timeframe (but are never even considered, discussed or treated)
  • GMO signatures
  • distribution anomalies inconsistent with natural tick migration patterns (And it ain’t from climate change! It’s from man-made tick redistribution out of airplanes & migrating birds & animals)
  • suppression of the Swiss Agent indicating systematic research concealment

In short, it’s wide-spread systemic fraud perpetrated upon an unsuspecting public, yet the answer always presented is to have the very agencies behind this fraud do an investigation on themselves!  It will never happen.  ‘Dog and pony show’ comes to mind.

We’re on our own and the quicker we embrace this salient fact, the quicker we will get better.

For more: